Aspirin™ can look back at a rich, long-standing history and exciting future. For 125 years, Aspirin™ has been empowering everyday health transformation for all. The proven role of Aspirin™ in OTC pain, inflammation, and fever management, as well as low-dose Aspirin™ Cardio for cardiovascular disease prevention, continues to make it a globally versatile and trusted brand.
“No other drug in the world has had such a fascinating and record-breaking history – a development that has not yet come to an end.”
Sir John Vane
Nobel Prize Winner
More than 7,500 million Aspirin pills a year11 allow millions to take care of their heart and live pain- and cold symptoms-free.
5,000 million pills helping hearts
2,400 million pills soothing pain
257 million pills and 134 million products relieving symptoms of cold
125 years of empowering health transformation
Dr. Felix Hoffmann synthesized a chemically pure and stable form of acetylsalicylic acid (ASA), the active ingredient in Aspirin™.
Aspirin™ was registered as a trademark. It was launched on the market in powder form and dispensed to customers in small paper bags. One year later, Bayer launched the analgesic in its classic tablet form.
Aspirin™ was made available without a prescription and became a best-seller in the USA.
Aspirin™ was featured in the Guinness Book of Records as the best-selling pain reliever in the world.
A box of Aspirin™ flew to the moon aboard Apollo 11.
A study reported that Aspirin™ can prevent ischemic stroke in appropriate patients.4 The World Health Organization (WHO) introduced its “Essential Drug List”.
John Vane received the Nobel Prize for Medicine. He discovered the anti-inflammatory properties of Aspirin™.
In Germany and a few other countries, Aspirin introduced Aspirin™ Protect, a low-dose Aspirin™ formulation for use by appropriate at-risk patients to prevent cardiovascular events.
Aspirin™ took place among medical advances, such as the stethoscope and artificial heart, when it was inducted into the Smithsonian Institution’s National Museum of American History, USA.
Publication in the journal Headache by Lampl et al reaffirmed the effectiveness of Aspirin™ as the first-line treatment of migraine or episodic tension-type headache.8
A new Aspirin™ product was introduced in Europe and Latin America countries. Acetylsalicylic acid microparticles were combined with sodium carbonate to help Aspirin™ dissolve more quickly, enter the bloodstream faster, and relieve pain twice as fast as previous Aspirin™ tablets.9,10
Facebook
LinkedIn
YouTubeSource.
1 Who List of Essential Medications: 17th List, March, 2011. http://whqlibdoc.who.int/hq/2011/a95053_eng.pdf (accessed March 22, 2013).
2 Weisman S, Graham D. Evaluation of the benefits and risks of low-dose Aspirin™ in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med 2002;162(19):2197–2202.
3 Antithrombotic Trialists’ (ATT) Collaboration. Aspirin™ in the primary and secondary prevention of vascular disease: collaborative metaanalysis of individual participant data from randomized clinical trials. Lancet 2009; 373:1849–1860.
4 Genton E, Barnett HJ, Fields WS et al. XIV. Cerebral ischemia: the role of thrombosis and of antithrombotic therapy. Study group on antithrombotic therapy. Stroke 1977;8(1):150–175.
5 Lewis HD Jr, Davis JW, Archibald DG et al. Protective effects of Aspirin™ against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 1983;309(7):396–403.
6 International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomized trial of Aspirin™, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997;349(9065):1569–1581.
7 Paul-Clark MJ, Van Cao T, Moradi-Bidhendi N et al. 15-epi-lipoxin A4-mediated induction of nitric oxide explains how Aspirin™ inhibits acute inflammation. J Exp Med 2004;200(1):69–78.
8 Lampl C, Voelker M, Steiner TJ. Aspirin™ is First-Line Treatment for Migraine and Episodic Tension-Type Headache Regardless of Headache Intensity. Headache 2012;52(1):48–56.
9 Voelker M.,Hammer M., Inflammopharmacology 2012;20:225-231.
10 Cooper SA., Voelker M., Inflammopharmacology 2012;20:225-242.
11 Bayer Internal Sales Report FY 2022.
